<DOC>
	<DOC>NCT00986362</DOC>
	<brief_summary>To evaluate the safety and preliminary efficacy of intravitreal microplasmin as an adjunct to conventional vitrectomy for the treatment of pediatric patients.</brief_summary>
	<brief_title>Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy</brief_title>
	<detailed_description />
	<mesh_term>Plasminogen</mesh_term>
	<criteria>1. Male or female infants or children 16 years of age or younger 2. Patient must be a suitable candidate for conventional 2port or 3port pars plana vitrectomy 3. Patient with attached vitreous somewhere in posterior pole 4. Patient's parent or guardian must be willing and able to comply with followup requirements 5. Patient's parent(s) must sign informed parental permission form and in the case of schoolage children the patient must sign assent form 1. Patient diagnosed with Stage 1, 2, 3 or 5 retinopathy of prematurity (ROP) at the time of surgery 2. Unclear media, which precludes assessment of the posterior pole such as a cataract or vitreal opacity 3. Active parental/guardian drug or alcohol use or dependence that, in the opinion of the site Investigator, would interfere with parent's or guardian's adherence to study requirements 4. Medical problems that make consistent followup over the treatment period uncertain. 5. Patient must not have participated in an investigational drug or device study in the prior 30 days 6. Female Patients of childbearing potential must not be pregnant or lactating.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Safety in pediatrics</keyword>
</DOC>